Nucleosomal DNA fragments in autoimmune diseases

Annals of the New York Academy of Sciences

Volumn 1075, Issue , 2006, Pages 318-327

  Holdenrieder, Stefan ^a   Eichhorn, Peter ^a   Beuers, Ulrich ^a   Samtleben, Walter ^a   Schoenermarck, Ulf ^a   Zachoval, Reinhart ^a   Nagel, Dorothea ^a   Stieber, Petra ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

AIH; Autoimmune disease; Caspases; Connective tissue disease; DNA; Nucleosomes; PBC; Plasma; PSC; Serum; SLE; Vasculitis

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; CASPASE; DNA FRAGMENT; NEUTROPHIL CYTOPLASMIC ANTIBODY; NUCLEOSOME ANTIBODY;

ANTIBODY PRODUCTION; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CONFERENCE PAPER; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; NUCLEOSOME; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; QUALITATIVE ANALYSIS; SERUM; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 33749581733     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1368.043     Document Type: Conference Paper

References (47)

1. KOUTOUZOV, S. et al. 2004. Nucleosomes in the pathogenesis of systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 30: 529-558.
2. BERDEN, J.H. 2003. Lupus nephritis: consequence of disturbed removal of apoptotic cells? Neth. J. Med. 61: 233-238.
3. LUGER, K. et al. 1997. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389: 251-260.
4. KORNBERG, R.D. & Y. LORCH 1999. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 98: 285-294.
5. STRAHL, B.D. & C.D. ALLIS. 2000. The language of covalent histone modifications. Nature 403: 41-45.
6. NELSON, S.M. et al. 2004. DNA and the chromosome-varied targets for chemotherapy. Cell Chromosome 3: 2.
7. HOLDENRIEDER, S. et al. 2001. Nucleosomes in serum of patients with benign and malignant diseases. Int. J. Cancer 95: 114-120.
8. VAN NIEUWENHUIJZE, A.E. et al. 2003. Time between onset of apoptosis and release of nucleosomes from apoptotic cells: putative implications for systemic lupus erythematosus. Ann. Rheum. Dis. 62: 10-14.
9. LICHTENSTEIN, A.V. et al. 2001. Circulating nucleic acids and apoptosis. Ann. N. Y. Acad. Sci. 945: 239-249.
10. HOLDENRIEDER, S. et al. 2001. Nucleosomes in serum as a marker for cell death. Clin. Chem. Lab. Med. 39: 596-605.
11. HENGARTNER, M.O. 2000. The biochemistry of apoptosis. Nature 407: 770-776.
12. HOLDENRIEDER, S. & P. STIEBER. 2004. Apoptotic markers in cancer. Clin. Biochem. 37: 605-617.
13. HENGARTNER, M.O. 2001. Apoptosis: corralling the corpses. Cell 104: 325-328.
14. STROUN, M. et al. 2000. The origin and mechanism of circulating DNA. Ann. N. Y. Acad. Sci. 906: 161-168.
15. NG, E.K. et al. 2002. Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. Clin. Chem. 48: 1212-1217.
16. RUMORE, P.M. & C.R. STEINMAN. 1990. Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone. J. Clin. Invest. 86: 69-74.
17. RUMORE, P. et al. 1992. Haemodialysis as a model for studying endogenous plasma DNA: oligonucleosome-like structure and clearance. Clin. Exp. Immunol. 90: 56-62.
18. HOLDENRIEDER, S. et al. 2005. Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR. Clin. Chem. 51: 1544-1546.
19. ATAMANIUK, J. et al. 2004. Increased concentrations of cell-free plasma DNA after exhaustive exercise. Clin. Chem. 50: 1668-1670.
20. ZEERLEDER, S. et al. 2003. Elevated nucleosome levels in systemic inflammation and sepsis. Crit. Care Med. 31: 1947-1951.
21. Lo, Y.M. et al. 2000. Plasma DNA as a prognostic marker in trauma patients. Clin. Chem. 46:319-323.
22. GEIGER, S. et al. 2006. Nucleosomes in serum of patients with early cerebral stroke. Cerebro. Vasc. Dis. 21: 32-37.
23. FISHBEIN, T.M. et al. 2004. Increased apoptosis is specific for acute rejection in rat small bowel transplant. J. Surg. Res. 119: 51-55.
24. AMOURA, Z. et al. 1997. Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. Arthritis Rheum. 40: 2217-2225.
25. KUROI, K. et al. 1999. Plasma nucleosome levels in node-negative breast cancer patients. Breast Cancer 6: 361-364.
26. SOZZI, G. et al. 2001. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 61: 4675-4678.
27. TREJO-BECERRIL, C. et al. 2003. Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients. Int. J. Cancer 104: 663-668.
28. GAUTSCHI, O. et al. 2004. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J. Clin. Oncol. 22: 4157-4164.
29. HOLDENRIEDER, S. et al. 2004. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 10: 5981-5987.
30. KREMER, A. et al. 2005. Nucleosomes in pancreatic cancer patients during radiochemotherapy. Tumor Biol. 26: 44-49.
31. BELL, D.A. & B. MORRISON. 1991. The spontaneous apoptotic cell death of normal human lymphocytes in vitro: the release of, and immunoproliferative response to, nucleosomes in vitro. Clin. Immunol. Immunopathol. 60: 13-26.
32. KOUTOUZOV, S. et al. 1997. Comparison of structural characteristics of antisubnucleosome and anti-DNA monoclonal antibodies derived from lupus mice. Ann. N. Y. Acad. Sci. 815: 327-330.
33. EMLEN, W. et al. 1994. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J. Immunol. 152: 3685-3692.
34. D'AURIA, F. et al. 2004. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J. Intern. Med. 255: 409-418.
35. SALLAI, K. et al. 2005. Antinucleosome antibodies and decreased deoxyribonuclease activity in sera of patients with systemic lupus erythematosus. Clin. Diagn. Lab. Immunol. 12: 56-59.
36. LICHT, R. et al. 2004. Decreased phagocytosis of apoptotic cells in diseased SLE mice. J. Autoimmun. 22: 139-145.
37. RADIC, M. et al. 2004. Nucleosomes are exposed at the cell surface in apoptosis. J. Immunol. 172: 6692-6700.
38. GABLER, C. et al. 2003. The putative role of apoptosis-modified histones for the induction of autoimmunity in systemic lupus erythematosus. Biochem. Pharmacol. 66: 1441-1446.
39. AMOURA, Z. et al. 2000. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum. 43: 76-84.
40. RAHMAN, A. & F. HIEPE. 2002. Anti-DNA antibodies-overview of assays and clinical correlations. Lupus 11: 770-773.
41. GHIRARDELLO, A. et al. 2004. Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients. J. Autoimmun. 22: 235-240.
42. SUER, W. et al. 2004. Autoantibodies in SLE but not in scleroderma react with protein-stripped nucleosomes. J. Autoimmun. 22: 325-334.
43. WILLIAMS, R.C. JR. et al. 2001. Detection of nucleosome particles in serum and plasma from patients with systemic lupus erythematosus using monoclonal antibody 4H7. J. Rheumatol. 28: 81-94.
44. GHILLANI-DALBIN, P. et al. 2003. Testing for anti-nucleosome antibodies in daily practice: a monocentric evaluation in 1696 patients. Lupus 12: 833-837.
45. CORTES-HERNANDEZ, J. et al. 2004. Antihistone and anti-double-stranded deoxyribonucleic acid antibodies are associated with renal disease in systemic lupus erythematosus. Am. J. Med. 116: 165-173.
46. SIMON, J.A. et al. 2004. Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology 43: 220-224.
47. WALLACE, D.J. et al. 1994. Antibodies to histone (H2A-H2B)-DNA complexes in the absence of antibodies to double-stranded DNA or to (H2A-H2B) complexes are more sensitive and specific for scleroderma-related disorders than for lupus. Arthritis Rheum. 37: 1795-1797.